The ALK Master Protocol study is currently exploring the usefulness of mutation testing using liquid biopsies followed by mutation-specific ALK TKI treatments in patients with ALK-positive, stage IV NSCLC who have experienced progression on next-generation ALK inhibitors (NCT03737994). This evidence concerns the gene ALK and non-small cell lung carcinoma.